ScreenerHero

DAREDare Bioscience, Inc.

NAS · US · Healthcare · Biotechnology · darebioscience.com
0.8199USD-0.55%Mkt Cap: 15.89M $P/E: —

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap15.89M $
Enterprise Value773.17K $
Revenue (TTM)1.37M $
Gross Profit734.39K $
Net Income (TTM)-13.40M $
Revenue/Share0.0970 USD
Last Price0.8199 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.95
PEG—
EV/EBITDA-0.09
EV/Revenue0.57
P/S11.48
P/B-21.87
EPS (TTM)-0.64
EPS (Forward)-0.41
52W Range
0.76502% of range3.780
52W High3.780 USD
52W Low0.7650 USD
Profitability
Gross Margin71.29%
Oper. Margin-1582.53%
EBITDA Margin0.00%
Profit Margin-1300.66%
ROE-471.37%
ROA-41.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-9.89M $
CapEx (TTM)385.28K $
FCF Margin-505.24%
FCF Yield-43.44%
Net Debt-11.60M $
Net Debt/EBITDA1.29
Balance Sheet
Debt/Equity0.93
Current Ratio0.99
Quick Ratio0.77
Book Value/Sh-0.0370 USD
Cash/Share0.8250 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJul 20, 2017
Splits
Last Split1:12
Split DateJul 1, 2024
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)8.333 USD
Upside (mean)+916.4%
Target Range5.000 USD – 12.00 USD
$5.000+916.4% to mean$12.00
# Analysts3
Ownership
Shares Out.19.38M
Float14.02M
Insiders6.65%
Institutions7.97%
Short Interest
Short Ratio4.5d
Short % Float5.64%
Short % Out.5.61%
Shares Short839.80K
Short (prev mo.)691.07K
Technical
SMA 501.648 (-50.2%)
SMA 2001.879 (-56.4%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)524.78K
Avg Vol (10d)1.91M
Technical Indicators
RSI (14)24.4
MACD-0.2087
MACD Signal-0.1760
MACD Hist.-0.0326
BB Upper1.629 USD
BB Middle1.217 USD
BB Lower0.8059 USD
BB Width67.62%
ATR (14)0.1482 USD
Vol Ratio (20d)0.53x